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Background: In southern Mexico, malaria transmission is low, seasonal, and persistent. Because many patients are
affected by two or more malaria episodes caused by Plasmodium vivax, we carried out a study to determine the
timing, frequency, and genetic identity of recurrent malaria episodes in the region between 1998 and 2008.
Methods: Symptomatic patients with more than one P. vivax infection were followed up, and blood samples were
collected from primary and recurrent infections. DNA extracted from infected blood samples was analyzed for
restriction fragment length polymorphism (RFLP) in genes encoding csp and msp3α, as well as size variation in
seven microsatellites.
Results: One hundred and forty six parasite samples were collected from 70 patients; of these, 65 patients had one
recurrent infection, four had two, and one had three recurrent infections. The majority of recurrent infections
occurred within one year of the primary infection, some of which were genetically homologous to the primary
infection. As the genetic diversity in the background population was high, the probability of homologous
re-infection was low and the homologous recurrences likely reflected relapses. These homologous recurrent
infections generally had short (< 6 months) or long (6–12 months) intervals between the primary (PI) and recurrent
(RI) infections; whereas infections containing heterologous genotypes had relatively longer intervals. The
epidemiological data indicate that heterologous recurrences could be either relapse or re-infections.
Conclusions: Genetic and temporal analysis of P. vivax recurrence patterns in southern Mexico indicated that
relapses play an important role in initiating malaria transmission each season. The manifestation of these infections
during the active transmission season allowed the propagation of diverse hypnozoite genotypes. Both short- and
long-interval relapses have contributed to parasite persistence and must be considered as targets of treatment for
malaria elimination programs in the region to be successful.
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Plasmodium vivax is responsible for 99% of malaria
cases in Mexico. In the 1980’s more than 100,000 cases
were reported each year. Due to intensive malaria con-
trol efforts carried out by the National Malaria Control
Program in the 1990s, the numbers of cases have been
declining ever since. Malaria transmission is general low
and seasonal, and is concentrated in residual foci along* Correspondence: lgonzal@insp.mx
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distribution, and reproduction in any mediumthe Pacific coast. In the past 10 years, ~80% of malaria
cases reported in Mexico have been from Oaxaca and
Chiapas provinces [1,2]. These malaria foci are vulner-
able to severe climate events as evidenced by malaria
outbreaks that occurred coincident with “el Niño” and
hurricane Paulina in 1998 in Oaxaca and Chiapas States,
and Hurricane Stan at the end of 2005 in southern
Chiapas.
P. vivax relapses are recurrent blood infections pro-
duced by latent parasites (hypnozoites) in the liver [3].
These episodes are of epidemiological significance, asCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sion in affected regions, which may be particularly rele-
vant where malaria transmission is seasonal. A person
inoculated with P. vivax sporozoites has from 5 to 80%
probability of producing latent hypnozoites after the pri-
mary attack [4]. These latent parasites are activated at
variable latency periods by as yet unknown factors [5,6].
The relapse pattern comprises the latency period and
number of relapse episodes; it may be influenced by para-
site strain, transmission dynamics, sporozoite inoculation
rate for different vector species, and host factors [5-8].
Primaquine (PQ) is an 8-aminoquinoline and is the
only licensed antimalarial drug currently available that
can be used to treat the dormant liver stage parasites
(hypnozoites). PQ has been used to prevent P. vivax re-
lapses in 1950 [9]. A 14-day PQ regimen (0.25 mg base/
kg/day) is currently recommended by the World Health
Organization (WHO) [10]. In some P. vivax affected
regions, parasites show reduced susceptibility to super-
vised PQ treatment, and higher PQ doses are required
to reduce recurrence rates [11-13]. In Mexico, standard
anti-malarial treatment guidelines included intermittent
single doses of chloroquine (CQ) and PQ combination
adjusted to age groups (from 10 and 0.75 for adults to
2.5 and ~0.16 mg/kg for children, respectively) [14] as
recommended by WHO [10], is administered once
monthly for three months, then no treatment is given
for the following three months. This treatment regimen
is repeated up to six times for a total of three years to
suppress recurrence onset [14,15]. Although this regi-
men has been administered for more than a decade,
there is no baseline data describing the recurrence char-
acteristics prevailing in southern Mexico. Currently,
there is no evidence suggesting the presence of chloro-
quine resistant P. vivax in the region.
In recent years, Mexico has been in a pre-elimination
phase due to significant reductions in malaria transmis-
sion [16]. It is now imperative to determine prevailing
relapse patterns in the affected regions in order to sup-
port effective pre-elimination practices. Relapse patterns
could evolve in response to changing drug pressure and
transmission dynamics. The genetic identity of relapsing
parasites is known to vary according to the transmission
intensity [17-19]. In very low transmission settings most
individuals are inoculated by no more than one infective
mosquito bite per year, often carrying a single genotype
infection, and the resulting primary and relapse episodes
are mostly caused by the same parasite genotype (gen-
etic homology) [17]. However, under more intense and
complex transmission where mixed genotype infections
and multiple infected bites are more common, many re-
lapse episodes may in fact be produced by parasites with
genotypes not initially detected in the primary infection
(genetic heterology) [18,19]. Additionally, it has beenproposed that relapse could be triggered by re-infection,
leading to frequent infections of mixed genotypes [5]. In
fact, one would predict a spectrum of homologous versus
heterologous relapse rates across different transmission
settings. In this report, molecular and epidemiological
analyses of recurrent malaria infections were carried out
in a malaria hypo-endemic region of southern Chiapas
between 1998 and 2008 in order to understand the timing
and molecular identity of recurrent P. vivax.
Methods
Sample collection
The study site (Tapachula and surrounding municipalities
in southern Mexico) comprises two main sub-regions with
alternating malaria transmission; in the temperate foothills
transmission occurs mainly during January-June and in
the coastal region during August-November. Symptomatic
patients who consented to donate a capillary or venous
blood sample were enrolled in the study. P. vivax infec-
tion was diagnosed by Giemsa-stained thick blood
smears at the Regional Center for Research in Public
Health (CRISP-INSP) during 1998–2008 [20-22]. Whole
blood was stored in liquid nitrogen, and then trans-
ferred to Whatman No.2 filter paper (Whatman Inter-
national, Ltd., Maidstone, England), dried and kept in
the dark. After collection, filter paper samples were
coded to block out identifying patient information, and
part of the paper was used in DNA extraction and
microsatellite analyses. All patients were treated by the
local malaria control program according to the Mexican
Malaria Treatment Guidelines [14]. Patients received
anti-malarial treatment whether or not they agreed to
give a blood sample. For the relapse study, both passive
and active follow up were carried out. A second blood
sample was collected from symptomatic patients who
returned to CRISP-INSP seeking diagnosis and treatment
of recurrent P. vivax infection (1998–2008). In addition,
other patients were visited at their villages monthly to de-
tect recurrent symptomatic infections (2005–2008). The
majority of the analyses reported here were carried out on
the paired blood samples with primary (PI) and recurrent
(RI) infections from a single patient. However, we also in-
cluded available non-paired samples from the region in
the estimate of background microsatellite genetic diver-
sity. The interval of infection-time between primary and
recurrent infections is reported in weeks.
Molecular analysis of P. vivax samples
One hundred μl of infected blood or 6 punches of 5 mm
diameter dried blood in filter paper were used to extract
DNA using the QIAampW DNA Blood Mini Kit (QIAGEN,
Hilden, Germany) following the manufacturer’s instruc-
tions. The DNA obtained was dissolved in water and
stored at −20°C until used. To determine the P. vivax
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analyzed, including variants in the circumsporozoite repeat
region (cspr) [23] and merozoite surface protein 3 alpha
domain (msp3α) [24-26], and 7 microsatellites positioned
on different chromosomes (Table 1) [27]. The cspr and
msp3α variants were genotyped by polymerase chain reac-
tion and restriction fragment length polymorphism (PCR-
RFLP) [23]. The microsatellite markers were genotyped
using capillary electrophoresis.
a) PCR-RFLP genotyping of the csp central repeat re-
gion (cspr). A nested PCR was carried out to amplify the
complete cspr using primers CSP-1 (5’-cgcactgcgggca
caatgtagatc-3’) and CSP-2 (5’-ggttacactgcatggagtcc-3’) for
the first round amplification, and F-Pv9a (5´-gccaacgg
tagctctaacttt-3´) [28] and CSP-RI (5'-aataagctgaaacaacca-
3') for the second amplification. The PCR reaction mixed
was prepared as follow: 2 μl 10X Buffer, 2 mM magne-
sium chloride, 0.2 mM dNTPs (Invitrogen, 10297018
Carlsbad, CA.), 10 μM each primer, 5 U GoTaqW Flexi
DNA polymerase (Promega, Madison WI) and approxi-
mately 100 ng of genomic DNA in a 20 μl final volume.
Two μl of the product from the first amplification was
added to the second PCR of the same setup. The PCR
conditions were as follow: first cycle at 95°C for 3 min,
followed by 35 cycles of 95°C for 30 sec, 57°C (for first
PCR) or 58°C (for second PCR) for 30 sec and 72°C for
1 min, and followed by a final extension at 72°C for 10
min using a MyCycler (Biorad, Hercules). The PCR
products were digested with AluI (New England Biolabs,
Beverly, MA) and BstI (Promega, Madison WI) which
have restriction sites in the cspr encoding Vk247 and
Vk210 regions, respectively [29]. DNA fragments were re-
solved in a 1.5% gel, visualized under a UV-transilluminatorTable 1 P. vivax microsatellites and their primers used for PC
length
Microsatellite Chromosome Repeat un
MS 040 6 AAAT
MS 092 5 GAA
MS 116 10 GAA
MS 033 3 CAT
MS 176 14 AT
MS 315 3 AT
MS 206 12 GTT
MS, microsatellite; F, forward; R, reverse.and photographed using the BioDoc-it™ digital photo-
documentation system (UVP Inc, Upland, California).
b) PCR-RFLP genotyping of the msp3α gene. The msp3α
gene was amplified in a nested PCR using the published
primers (P1, P2, N1 and N2) and a modified version of a
previously reported protocol [30]. The PCR was prepared
as follow: 2 μl 10X buffer, 1.875 mM magnesium chloride,
0.5 mM of dNTPs (Invitrogen, Carlsbad, CA.), 25 pM of
each primer P1 and P2, 1.25 U of GoTaqW Flexi DNA poly-
merase (Promega, Madison WI) and 1 or 5 μl of genomic
DNA extracted from whole or dried blood, respectively, in
a final PCR volume of 20 μl. The first PCR was run at 95°C
for 3 min, followed by 35 cycles of 94°C for 60 sec, 56°C
for 60 sec and 72 °C for 2.5 min, and a final extension cycle
at 72°C for 10 min. The second round of PCR reaction was
carried out with N1 and N2 primers using the same PCR
reaction after addition of 2 μl of first PCR product into a
20 μl mixture. The reaction was run at 95°C for 2 min,
followed by 30 cycles of 94°C for 60 sec, 62°C for 60 sec
and 72°C for 1.5 min, and a final extension cycle at 72°C
for 10 min. For twenty-seven samples that failed to amplify,
magnesium chloride and dNTPs were increased to 2.5 mM
and 1.0 mM, respectively, and PCR conditions were al-
tered. A total of eight samples did not amplify under either
PCR conditions. PCR products were digested with AluI
(New England BioLabs, Beverly, MA), which was used to
distinguish multiple msp3α alleles for parasites from dis-
tinct geographic regions such as Papua New Guinea [30],
India [31], Thailand [26], and Iran [23]. The digested paired
DNA samples were separated in 2% agarose gels and
stained with ethidium bromide and photographed.
c) Microsatellite (MS). Seven MS were also used to
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ogous infections, because MS are generally more vari-
able than nucleotide substitutions. In addition, 236
non-recurrent samples collected during the same time
period were also typed using the same MS in order to pro-
vide background diversity and marker performance esti-
mates. Samples were scored as mixed genotypes if a MS
marker produced a minor peak ≥ 33% of the primary peak.
MS primers are listed in Table 1. Due to limited DNA
quantity or quality for some samples, we were not able to
obtain microsatellite information for all the samples.
Data analysis
Malaria cases reported by the Sanitary Jurisdiction VII
during 1998–2007 were compiled in order to calculate
the annual parasitic index, defined as number of cases/
1,000 individuals (from affected villages)/per year. From
this we estimated the number of cases/1,000 individuals/
2-month intervals in order to compare rates between
high and low transmission periods. The case report in-
cludes all cases confirmed by microscopic analysis of
thick smears from all institutions of the corresponding
jurisdiction. To characterize the recurrent patterns in
the study region, a database was compiled to identify the
number of malaria episodes per person indicating name,
gender, age, village, municipality of origin and previous
malaria infections (self-reported or by a family member).
The number of malaria cases diagnosed per two-month
period was plotted to simulate transmission dynamics
and to identify intervals with minimum risk of re-
infection that could be used to identify putative heterol-
ogous relapse episodes. For patients identified as having
more than one infection, the time-interval between
primary and recurrent infections was estimated starting
with the day the sample was collected for P. vivax
diagnosis. Once malaria episodes were associated with
individual patients, all samples were coded and all the
patient information was masked. The original database
was secured at the study investigator’s office. Patients
registered between 2005 and 2008 as having more than
one episode were confirmed by a home-visit.
For putative relapse identification, blood samples from
patients with more than one episode and with good
genotype data, comprising at least cspr and msp3α geno-
types, and/or 6–7 MS, and the malaria epidemiology
data were used. Recurrent infections showing similar
cspr and msp3α genotypes as the primary infections
were defined as homologous. The correspondence be-
tween cspr-msp3α and MS heterology vs homology was
determined. Heterologous recurrent infections detected
when transmission was low or non-existent (based on
malaria case records) may in fact be heterologous re-
lapse. Pairs of samples with mixed genotype infections
detected in either the primary or recurrent infectionwere not included in the analysis. Relapse episodes were
grouped according to their time as follows: 1) early (1–
26 weeks), long (27–52 weeks) [32], or late (> 52 weeks).
We calculated the ratio of the number of homologous
versus heterologous recurrences within 52 weeks and >
52 weeks. All microsatellite analyses were carried out as
described [27] using GenAlEx v 6.5 [33].
All MS analyses were blinded to the relationship be-
tween samples and their origins. The baseline population
diversity was derived from MS genotype data from 326
non-recurrent infections collected during the 10 year
study period. The seven MS loci were used in combin-
ation to calculate the likelihood that two infections have
the same seven-locus genotype by chance by taking the
product of the individual homozygosities [34]. Chi-square
and t-test (at 95% confidence) were carried out in STATA
9.0 (Stata Corporation LD).
Ethical approval
The protocol for sample collection was approved by the
Ethics Committee of the National Institute of Public
Health (INSP), Mexico. Written informed consent was
obtained from all patient and/or their guardians for pa-
tients below 18 years old.
Results
Transmission dynamics and temporal pattern of recurrent
malaria cases compiled from the study region during
1998–2007
During this period, the annual parasitic index (API) fluctu-
ated between 0.58 and 3.4, and between 0.25 and 2 for
1,000 individuals living in the affected villages or the entire
municipality, respectively. The minimal number of malaria
cases reported per 1,000 individuals/2 months ranged from
0.031 to 0.41 across all years. In contrast, the highest trans-
mission levels occurred during the dry season, with be-
tween 0.43 and 1.9 cases per 1,000 individuals/2 months.
We therefore set a high transmission lower bound cut-off
at ≥ 0.4 cases/1,000 individuals/2 month across the 10 year-
period. From 7,694 malaria reports included in the data-
base, 8.1% (n=626) of patients were identified as having one
or more recurrent P. vivax infections. None of the recur-
rences occurred within 28 days (CQ surveillance period);
all recurrences occurred from 5 weeks to several years after
the primary infection. Among those, 25.2% occurred ≤ 26
weeks, 46.3% occurred within 27 and 52 weeks, and 28.4%
occurred ≥ 105 weeks after the primary infection (Figure 1).
From the total recurrent infections, 88.2% reported two
malaria episodes, 9.7% had three malaria episodes, and only
a few patients had three to six recurrent episodes.
cspr-msp3α genotypes and genetic diversity
Genotypes from 146 blood samples collected from 70
patients with more than one infection were scored based
Table 2 Sample size, performance measures and diversity
parameters for the nine molecular markers used to type
the recurrent sample pairs used in this study
Marker N GFR (%) Na % polyclonal HE
(PI/RI) (PI/RI) (PI/RI) (PI/RI) (PI/RI)
msp3α 49/56 27.1/25.3 8/8 5.7/5.3 0.743/0.739
csp repeat 69/74 1.4/1.3 2/2 5.7/5.3 0.492/0.505
MS 40 62/69 0/0 5/5 0/0 0.616/0.59
MS 92 62/69 0/0 8/9 1.9/1.9 0.754/0.806
MS 116 61/68 1.6/1.4 12/11 0/0 0.822/0.744
MS 33 58/69 6.5/0 7/8 3.7/1.9 0.706/0.63
MS 176 49/63 21.0/8.8 6/6 0/0 0.692/0.747
MS 315 59/67 4.8/2.9 5/5 0/3.8 0.593/0.62
MS 206 50/57 19.4/17.4 10/10 0/0 0.825/0.831
PI, primary infection; RI, recurrent infection.
N, number of samples; GFR, genotype failure rate, Na, number of alleles,
HE,effective heterozygosity.
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infections contained the same genotype(s) as the primary
infection (PI), as well as to detect mixed genotype infec-
tions (Additional file 1). Among these patients, 65 had
one recurrent infection (RI), four had two RI, and one
had 3 RI. The cspr genotype was determined for all but
two samples (one pair with insufficient sample) (Table 2).
RFLP-msp3α genotypes were successfully obtained for
117 paired samples from a subset of 56 patients. A con-
served ~2 kb msp3α product was amplified in all these
samples except from patient 58 that had a ~1.5 kb
fragment. Two cspr genotypes (corresponding to vk210
and vk247) and eight msp3α genotypes were identified
(Figure 2), and a total of 113 single P. vivax msp3α
genotype infections were detected. Among the eight
msp3α genotypes, genotype A, B, and C comprised the
majority (85.8%). All samples with the msp3α-A geno-
type also had the cspr vk247 genotype. Samples with
msp3α-B or msp3α-C had either cspr vk210 or vk247 ge-
notypes. There were five other less common msp3α ge-
notypes; all have cspr vk210. Genotype D was detected
in both PI and RI of two patients; E was detected in PI
and RI of three patients; whereas G and J were detected
in PI and RI from a single patient each (patient 58 and
59 respectively). Also, both samples from patient 58 had
a unique msp3α genotype (H) with a fragment size of 1.5
kb. These rare genotypes did not cluster in time but ra-
ther were collected throughout the 10-year sampling
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Figure 1 Distribution of recurrent intervals for P. vivax
infections. All recurrent P. vivax infections documented in the
records of the Malaria Control Program (Jurisdiction VII of Chiapas)
during 1998–2007 (n=590, comprising 94% of all the samples
excluding those with extreme longer intervals. PI, primary infection;
RI, recurrent infection).rarity of these less common genotypes, it is likely that
their presence in both the PI and RI infections of indi-
vidual patients was due to relapse episodes.Microsatellite variation
Among the recurrent sample pairs, a subset of 62
primary (PI) and 69 recurrent (RI) infections were suc-
cessfully genotyped using MS markers (Table 2 and
Additional file 1). In addition, 326 non-recurrent sam-
ples were genotyped at 4–7 MS markers to obtain base-
line information on population diversity (Table 3). Of
these, 312 were successfully typed for all microsatellite
markers. The number of alleles ranged from 6−15 for
the baseline samples and from 5−12 for the recurrent
samples (Tables 3 and 2). Effective heterozygosity (He)
for the seven MS used in this study ranged from 0.555-
0.818 (Table 3). MS He declined slightly over the 10 year
period (Figure 3A). Given the decline in the number of
malaria cases in the region starting in 2001, it is perhaps
surprising that diversity did not show a steeper decline
in later years, although this may be explained by an in-
crease in sample size (Figure 3). When the seven MS loci
are used in combination as we have done here, the likeli-
hood that two infections have the same seven-locus
genotype by chance is negligible (πPi = 1.39 × 10
-4). In-
deed, more than one MS haplotype could be found in
parasite isolates with identical csp-msp3α genotypes. For
most of the patients with rare msp3α genotypes D, E
and G (patient 7, 23, 38, 43, 46 and 66), where relapse
rather than re-infection was suspected, heterologous
microsatellite alleles were found in the RI samples. Two
of six patient samples had one new microsatellite allele
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Figure 2 Plasmodium vivax msp3α genotypes. PCR products were digested with Alu I, and the digested products are separated side-by-side
with their undigested products on agarose gels. a) Shows different genotypes indicated by capital letters underneath. b) Lanes 1, 3, 5, 7, 9, and
11 are undigested products of ~2.0 kb, and lanes 2, 4, 6, 8, 10, and 12 were the same products digested with Alu I. Lane 2 presents genotype C;
lane 4, 10, and 12 present genotype B; lane 6 and 8 are mixed genotypes of A+C; c) genotype G; d) genotype D; and e) genotype H. m, 100 bp
DNA ladder.
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pairs of infections as homologous, based on the rare but
identical msp3α alleles and that 1–2 single unit differ-
ences in microsatellite alleles between infections could
be due to DNA replication slippage within the patient.Table 3 Sample size, performance measures and diversity
parameters for the seven microsatellite markers used to
type 326 baseline, non-recurrent samples collected
between 1998 and 2007
Marker N GFR (%) Na % polyclonal HE
MS 40 321 1.5 6 2.15 0.555
MS 92 325 0.3 11 1.2 0.743
MS 116 326 0 15 0.8 0.762
MS 33 326 0 12 1.2 0.686
MS 176 319 2.2 8 0.0 0.665
MS 315 324 0.6 8 1.2 0.63
MS 206 323 0.9 15 - 0.818
N, number of samples; GFR, genotype failure rate, Na, number of alleles,
HE,effective heterozygosity.Relapse criteria based on microsatellite and csp-msp3
genotypes
Thirty nine paired samples produced genetic marker in-
formation for all three genetic marker sets. Among the
39 pairs, ten had heterologous cspr and/or msp3α geno-
types and all seven of them had three or more heterol-
ogous MS (patients 28, 29, 30, 37, 63, 65, 67), another
one had two of six heterologous MS (patient 53) and
only two pairs had 5 of 6 homologous microsatellites
(patients 3 and 18) (Figure 4, Table 4 and Additional file
1). In contrast, 29 patients had the same cspr-msp3α
genotype and > 80% homology of six or seven MS. In
particular, 14 pairs of samples (patients 6, 7, 9, 17, 20,
21, 34, 36, 38, 45, 46, 61, 63RI2, 66) had the same alleles
across all three-marker sets. However, four sample pairs
with homogeneous cspr-msp3α genotypes had two of six
(patient 25), or two of seven (patients 8, 19RI1, 42)
heterologous MS. A single patient with homogeneous
cspr-msp3α genotypes had three of six heterologous MS
(patient 59). In spite of this, high agreement across











































































1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 3 Microsatellite diversity and Plasmodium vivax infection rate in southern Mexico during a 10-year period. A. Pattern of allelic
variation for 7 microsatellite loci using 474 bloodspot samples collected over 10 years. Grey, mean number of alleles (Na); white, mean number of
alleles ≥ 5%; black line, mean effective heterozygosity (He = [n/(n-1)]×1-
P
pi
2), shows a slight but persistent decrease over the time frame (R2 =
0.3109). B. Number of malaria cases per 1,000 people during a 10 year period across the entire study area (black bars), and within villages with
positive malaria cases only (white bars). API: number of cases per year per 1,000 people.
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or microsatellites (Chi-square; p=0.003).
More homologous genotypes from patients with short
interval between PI and RI
The average duration between PI and RI for those hom-
ologous RIs (by cspr/msp3α/MS; n=22) was 41.5 ± 44.3
weeks, which was significantly different from those clas-
sified as heterologous RIs by cspr and/or msp3α (128.4 ±
104 weeks; n=10) (t-test; p=0.0022). Indeed, sample pairs
with the same cspr-msp3α genotypes and a high degree
of homology among microsatellite markers also had
shorter recurrent intervals than those with heterologous
msp3α or microsatellites (Figure 4, Table 4 and Additional
file 1). The majority (76.6%) of paired samples with a
latency period between five and 52 weeks were consid-
ered genetically homologous. The frequency of homolo-
gous recurrences declined gradually as the time interval
between infections increased to 53–104 weeks and
greater (total of 17.4%), (Table 4). The ratio of the num-
ber of homologous versus heterologous recurrences was
higher within 52 weeks (4.5) than > 52 weeks (0.35)(Table 5). Homologous recurrent episodes occurred in
people of both sexes and all ages, and originated from
different locations throughout the transmission area
(Additional files 1 and 2).
We observed more than two episodes of P. vivax mal-
aria during the study period in five patients, including
two patients who suffered three symptomatic malaria
episodes (patients 19 and 43; Additional file 1). In both
cases, parasites collected from all three episodes appear
to be homologous based on our criteria for the marker
set, although for patient 43 some data was missing (this
episode was not included in the previous analysis)
(Additional file 1). These putative homologous infec-
tions had latency periods of 27 and 43 weeks (patient
43), and 43 and 60 weeks (patient19). Interestingly, pa-
tient 51, also with three infections, showed a mixed PI
and two different RI at 34 and 46 week intervals. Al-
though MS data was not obtained for the PI, based on
our criteria for cspr-msp3α, the first but not the second
R1 was likely homologous to the PI. Patient 5 suffered 4
malaria episodes, two in 2002 with the same cspr-msp3α
genotype (13 weeks apart), and the other two episodes


















Figure 4 Concordance between P. vivax cspr-msp3α and
microsatellite patterns for primary and recurrent infections
with different latency periods (n=39 pair samples). Each data
point indicates one sample pair (PI and RI). Circles indicate paired
infections with homologous cspr-msp3α genotypes. Brown circles,
rare msp3α genotypes (D, E, G); orange circles, common msp3α
genotypes (A, B, C). Green triangles indicate paired infections with
heterologous cspr-msp3α genotypes.
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episodes were identical to each other but differed from
the first and second episodes in their msp3α alleles (B
versus A). There were also six polyclonal infections
detected by cspr-msp3α in the PI only (patients 10, 26,
32, 35, 51, 70) that corresponded to 75% of the total
detected, while the other two (25%) were in the RI only
(patients 2, 52) (Additional file 1).
According to the transmission intensity estimated for
the study region, 71.4% (50 of 70 patients) of primary in-
fections occurred during the high transmission season.
In areas of seasonal transmission, relapses can occur
immediately prior to the initiation of malaria transmis-






*By cspr *By MS
+msp3α (N)
(N)
5-13 4 2 1
14-26 2 1 -
27-40 9 - 7
41-52 5 1 3
53-69 2 - -
70-104 1 - -
≥105 1 - -
N total 24 4 11
*only these marker results were obtained; **msp3α genotype J; N, number of recurr
(merozoite surface protein 3α gene) and MS (microsatellite). Time-interval of homol
and 52 weeks.observed both incidences in our study. There were no
differences in the ratios between the number of homolo-
gous and heterologous recurrences during low versus
high transmission seasons (p=0.957) (Table 5) and were
similarly distributed in the region (Additional file 3). In
addition, no obvious correlation was observed between
any genotypes and latency period; the msp3α A, B and C
genotypes were found in relapses of short (5–26 weeks),
long (27–52 weeks) or even late (over 52 weeks) latency
periods. Similarly, patients infected with low frequency
genotypes cspr vk210 and msp3α-D, E, G, H and J
showed recurrence within 17–44 weeks, although the
relatively shorter latency periods were likely associated
with homologous relapses, compared with heterologous
recurrences (relapse or re-infections). Heterologous and
mixed genotype recurrent infections occurring during
the lowest transmission season are likely relapses (e.g.
patients 1, 2, 3 and 5).
Discussion
Relapse episodes can be caused by parasites that are either
homologous or heterologous to the primary infections. If
a patient is infected with a single parasite genotype, the re-
lapse will have the same genotype as the PI [17]. If, how-
ever, a patient is infected with more than one parasite
genotype, the relapse could result from any one of those
genotypes. Many factors may contribute to the latency
and frequency of relapse, including the number of sporo-
zoites inoculated, host immunity, co-infection with other
parasites such as Plasmodium falciparum, drug treatment,
and the genetic composition of P. vivax strains [5].
A better understanding of the mechanism of relapse
and the development of methods to distinguish relapse
from new infections or recrudescence will greatly facili-
tate efforts to control and eliminate P. vivax malaria. PQ
is currently the only licensed drug that has been shownsingle genotype infections
Genetic heterology: N total
Subtotal By any of the three










ent infections. All markers correspond to csp (circumsporozoite gene), msp3α
ogous paired samples of rare msp3α genotypes (D, E, G, H, J) were within 14
Table 5 Numbers and ratios of homologous and
heterologous infections during low and high
transmission seasons
Group # Hom #Het Ratio *P-value
PI_LTS 16 8 2.00 0.957
PI_HTS 35 18 1.94
RI<52W 41 9 4.50 0.0001
RI>52W 6 17 0.35
Hom, homologous infections; Het, heterologous infections;
Ratio, ratio of homologous infection over heterologous infection;
PI_LTS, Primary infection during the low transmission season; PI_HTS, primary.
infection during the high transmission season; RI < 52W, recurrent infection
within 52 weeks of the primary infection; RI > 52W, recurrent infection at or
after 52 weeks.
following the primary infection.
* Chi-square; IC 95%.
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making treating P. vivax malaria and interrupting trans-
mission more difficult. In southern Mexico, the current
antimalarial guideline is designed to suppress recurrent
infections only if the drugs are administered to patients
at the onset of the blood infection. However, putative re-
lapse infections were detected within and between the
three-month timeframe of the single dose administration
strategy, warranting reconsideration of the guidelines.
Several studies have employed genetic markers to fa-
cilitate identification of P. vivax relapse infections
[17,26,30,39,40], and WHO has recommended the use
of at least one polymorphic marker to aid distinction
between homologous and heterologous infections [10].
In this study, we used two types of polymorphic markers,
PCR-RFLP size polymorphism in cspr and msp3a and a
set of seven microsatellites, to develop criteria for identify-
ing putative relapse infections in southern Mexico. While
only two cspr genotypes (vk210 or vk247) were found in
our samples, eight alleles were detected for msp3a. Geno-
typing results from the combination of these two genetic
markers appeared to be consistent with those obtained
using microsatellites, e.g. sample pairs with the same cspr-
msp3a genotype also had highly similar microsatellite
alleles. Recurrent infections in this low transmission, pre-
elimination setting [41,42] were considered being relapses
if: 1) the PI and RI had exactly the same cspr-msp3a geno-
types and > 80% homologous microsatellite alleles; 2) the
PI and RI had the same rare cspr-msp3a genotype, and 3)
the heterologous RI sample occurred during a non-
transmission period when the chance of a new infection
was vanishingly small. These criteria allow us to define re-
lapses with a certain degree of confidence, although there
is still a possibility of the appearance of new infections
with the same genotype during local outbreaks (rapid ex-
pansion of parasites with the same genotype), as well as
the possibility that mutations can occur during parasite
replication within a host, particularly for MS markers thathave relatively high mutation rates due to replication slip-
page. In a recent study, an infection with identical cspr-
msp1-msp3 and MS genotypes (1–2 MS loci that differs
by a single repeat unit) or identical cspr-msp1-msp3 were
considered as homologous infection [43]. Our first criter-
ion was similar to those employed by Kim et al. [43]. Be-
cause our samples were from a low transmission region,
we also considered annual transmission rate and the rela-
tively low possibility of infecting parasites with multiple
genotypes in determining relapse or re-infection. How-
ever, even though we used nine molecular markers to clas-
sify infections in this study, our classifications might miss
some heterologous relapses using these criteria. Finally,
the methods employed here, compared with, for example,
deep-sequencing of all infections, may not identify all ge-
notypes in either the PI or RI.
In southern Chiapas, Mexico, transmission mainly oc-
curs on temperate zone hillsides and is seasonal, once
per year generally lasting for 4–6 months; it begins after
the rain ends and continues throughout the dry season
until the onset of the next rainy season (January-June).
Southern Mexico is also a region with low transmission
intensity and thus provides an ideal setting for studying
relapse in the field because of the low mixed genotype
infection rate (< 10%) and the low likelihood that a pa-
tient will receive more than one infective bite within one
year [19,35]. Our study of 76 recurrent symptomatic in-
fections caused by P. vivax in this region showed a large
percentage of relapse episodes occurring within the first
52 weeks, based on our definition of relapse, with a ma-
jority of these occurring between 27–52 weeks. Most
parasites causing recurrent infections > 52 week after
the primary episode were genetically different from the
parasites in the PI, suggesting heterologous relapse or
re-infections. A few recurrent infections with late inter-
vals (60, 67, 81, and 226 weeks) were also considered to
be relapses based on either genetic homology between
the PI and RI, and/or occurrence of the RI during the
time of year when no known transmission was occur-
ring. Similarly, in El Salvador, 70% of observed recurrent
infections happened within 12 months of the PI, and in
the absence of mosquito transmission, and were attrib-
uted to relapse [35]. However, it is possible that some
heterologous recurrences detected in the high transmis-
sion season may be relapses, and some homologous re-
currences may correspond to re-infections because the
resolution of using a limited number of genetic markers
may not be sufficient to identify mixed genotypes or be-
cause recurrence infections were derived from parasites
of same genotypes (outbreaks).
We found no association between P. vivax genotypes
and relapse latency, but we cannot entirely rule out this
possibility because our sample size was relatively small.
Relapse, as defined in the literature, conforms to two
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mainly within the first 3–6 months after primary infec-
tion, as represented by the tropical strain "Chesson" iso-
lated from the Pacific Coast of Asia and those P. vivax
parasites found in Thai and Vietnamese [44]. In regions
with stable malaria transmission and mild climate, para-
sites typically exhibit short-latency relapse, as seen in
Thailand [45], Colombia [46], French Guyana [47] and
Brazil [48,49]. In contrast, relapse with a relatively long
latency period (7 to 14 months) is represented by the
template strain "St Elizabeth" isolated from the Atlantic
coast [5,50,51]. These criteria are similar to those pro-
posed by Adak based on several P. vivax relapse studies
in India [32]. The relatively long-term relapses detected
here are consistent with relapses observed in other tem-
perate zones [5,6,52]. During 2004–2005, malaria trans-
mission in southern Mexico declined precipitately, with
only a few malaria cases reported. This reduction did not
lead to a concomitant reduction in parasite genetic diver-
sity based on our microsatellite data (Figure 3) but may
have selected for parasites capable of relapsing for longer
intervals. In contrast, Hurricane STAN in October, 2005,
created an environment that greatly increased parasite
transmission, and may have altered relapse patterns in
subsequent years. Increases in rainfall can have a dramatic
impact on parasite transmission and, in theory, relapse
patterns. For example, the incidence of mixed-genotype
infections would be expected to increase due to increased
parasite transmission. In addition, under conditions of in-
creased transmission, hypnozoite-infected patients are
more likely to receive additional bites from infected mos-
quitoes [36]. In Central America, relapses were reported
to occur between 3 and 10 months, with the relapse inter-
val varying between parasite strains and subjects, perhaps
indicating adaptation to the unique local ecological envir-
onment, including transmission intensity and length of
the dry season [8,19]. Late interval relapses appear to be
less common, but have been documented in other regions,
with intervals ranging from between one and two years
[32,53], up to four years [54] and even twenty years [55].
In our study, we documented one putative relapse with a
226-week interval (> 4 years) containing a single haplotype
in both PI and RI samples, and exhibiting perfect genetic
homology across all genetic markers. Heterologous re-
lapses were rarely observed in this study, and this may re-
flect a low rate of mixed genotype infections, typical of a
low transmission area. With the exception of patient 2, all
relapse episodes were produced by a single P. vivax geno-
type supporting the clonal activation of hypnozoites [18].
Conclusions
In summary, our study represents the first investigation
of P. vivax relapse in southern Mexico using molecular
markers, and contributes to the global understanding ofrelapsing malaria. We demonstrate that a large number
of putative relapse infections occurred within 52 weeks
(one year) of the initial infection, and were largely hom-
ologous to the primary infection. They were located
mainly in the foothills, which is consistent with observa-
tions from other regions with similar temperate zone
climate conditions. Genetic markers when analyzed in
combination with transmission information can provide
a useful tool to characterize recurrent infections.
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Additional file 1: Data of P. vivax primary and recurrent infections
and genetic results.
Additional file 2: Geographic distribution of P. vivax recurrent
episodes in Southern Chiapas, Mexico. Each circle correspond to one
village. Patients with single and genetic homologous primary and
recurrent infections are indicated in dark blue. Those with mixed primary
infection with a genetic related or unrelated single recurrent infection are
in blue and bright blue, respectively. Heterologous recurrent episodes are
indicated in white. * indicate one mixed recurrent infection, likely a
relapse.
Additional file 3: Temporal distribution of P. vivax homologous and
heterologous recurrent single infections. Brown arrows indicate
homologous PI and RI genotypes and blue arrows indicate heterologous
PI and RI genotypes. Round spot indicate primary blood infection and
the arrow head indicate the recurrent blood infection. Thick arrows
indicate rare msp3α genotypes. Patient number is indicated at the arrow
side. Red line indicate cut-off value for low transmission setting.
Abbreviations
CQ: Chloroquine; PQ: Primaquine; PI: Primary infection; RI: Recurrent infection;
csp: Circumsporozoite protein; msp3α: Merozoite surface protein 3 alpha;
MS: Microsatellites; PCR: Polymerase chain reaction; RFLP: Restriction
fragment length polymorphism.
Competing interests
The authors declare no competing interests.
Authors’ contributions
LGC participated in the conception and design of the study, analysis and
interpretation of data, preparing tables and figures, and manuscript writing;
JM participated in microsatellite analysis and manuscript writing; GC and FSV
carried out the PCR-RFLP analysis of genes csp and msp3α; MS participated
in patient follow-up in the field and collection of P. vivax samples, and
preparation of figures; DJ participated in microsatellite analyses; preparing
figures and tables, interpretation of data and manuscript writing; XS
participated in interpretation of data and manuscript writing; RT and VCH
prepared a data base of the 10-year malaria case report and data analysis. All
authors read and approved the final manuscript.
Acknowledgments
This work was supported by funds of CONACYT salud-2004-119 and CB-
2009-01-131247, and by the Divisions of Intramural Research at the National
Institute of Allergy and Infectious Diseases. We thank the technical
assistance of J.A. Nettel in DNA extraction and patient handling.
Author details
1CRISP, National Institute for Public Health, Tapachula, Chiapas 30700, Mexico.
2Laboratory of Malaria and Vector Research, NIAID, National Institutes of
Health, Bethesda, MD 20892, USA. 3Sanitary Jurisdiction VII, Ministry of Health,
Tapachula, Chiapas, Mexico.
Received: 3 September 2012 Accepted: 3 April 2013
Published: 18 April 2013
Gonzalez-Ceron et al. Parasites & Vectors 2013, 6:109 Page 11 of 12
http://www.parasitesandvectors.com/content/6/1/109References
1. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades:
Dirección general de epidemiología: Secretaria de Salud México. http://www.
dgepi.salud.gob.mx/2010/plantilla/intd_boletin.html.
2. Betanzos AF: La malaria en México. Progresos y desafíos hacia su
eliminación Challenges and progress in the elimination of malaria in
Mexico [Challenges and progress in the elimination of malaria in Mexico.
Bol Med Hosp Infant Mex 2011, 68(2):159–168.
3. Cox FE: History of the discovery of the malaria parasites and their
vectors. Parasit Vectors 2010, 3(1):5.
4. Baird JK, Hoffman SL: Primaquine therapy for malaria. Clin Infect Dis 2004,
39(9):1336–1345.
5. White NJ: Determinants of relapse periodicity in Plasmodium vivax
malaria. Malar J 2011, 10:297.
6. Verhave JP: Experimental, therapeutic and natural transmission of
Plasmodium vivax tertian malaria: scientific and anecdotal data on the
history of Dutch malaria studies. Parasit Vectors 2013, 6(1):19.
7. Contacos PG, Collins WE: Letter: Malarial relapse mechanism. Trans R Soc
Trop Med Hyg 1973, 67(4):617–618.
8. Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA: Studies on
the characterization of Plasmodium vivax strains from Central America.
Am J Trop Med Hyg 1972, 21(5):707–712.
9. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report
from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med
Hyg 2006, 75:402–415.
10. WHO (Ed): Guidelines for malaria treatment. Secondth edition. Geneva; 2010.
http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html.
11. Baird JK, Schwartz E, Hoffman SL: Prevention and treatment of vivax
malaria. Curr Infect Dis Rep 2007, 9(1):39–46.
12. Goller JL, Jolley D, Ringwald P, Biggs BA: Regional differences in the
response of Plasmodium vivax malaria to primaquine as anti-relapse
therapy. Am J Trop Med Hyg 2007, 76(2):203–207.
13. Spudick JM, Garcia LS, Graham DM, Haake DA: Diagnostic and therapeutic
pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin
Microbiol 2005, 43(2):978–981.
14. Secretaria de Salud: NORMA Oficial Mexicana NOM-032-SSA2-2002, Para la
vigilancia epidemiológica, prevención y control de enfermedades transmitidas
por vector. México; 2002. http://www.salud.gob.mx/unidades/cdi/nom/
032ssa202.html.
15. Mendez Galvan JF, Guerrero Alvarado J, Gonalez Mora M, Perez Landa M,
Quintero Cabanillas R: Evaluation of an alternative scheme of treatment
for the control of malaria. Salud Publica Mex 1984, 26(6):561–572.
16. WHO: World Malaria Report. Geneva; 2009. http://www.who.int/malaria/
world_malaria_report_2009/en/index.html.
17. Craig AA, Kain KC: Molecular analysis of strains of Plasmodium vivax from
paired primary and relapse infections. J Infect Dis 1996, 174(2):373–379.
18. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q: Relapses of
Plasmodium vivax infection result from clonal hypnozoites activated at
predetermined intervals. J Infect Dis 2007, 195(7):934–941.
19. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A,
Guthmann JP, Nosten F, Carlton J, Looareesuwan S, et al: Relapses of
Plasmodium vivax infection usually result from activation of
heterologous hypnozoites. J Infect Dis 2007, 195(7):927–933.
20. Gonzalez-Ceron L, Rodriguez MH, Nettel JC, Villarreal C, Kain KC, Hernandez
JE: Differential susceptibilities of Anopheles albimanus and Anopheles
pseudopunctipennis to infections with coindigenous Plasmodium vivax
variants VK210 and VK247 in southern Mexico. Infect Immun 1999, 67(1):
410–412.
21. Gonzalez-Ceron L, Rodriguez MH, Santillan F, Chavez B, Nettel JA,
Hernandez-Avila JE, Kain KC: Plasmodium vivax: ookinete destruction and
oocyst development arrest are responsible for Anopheles albimanus
resistance to circumsporozoite phenotype VK247 parasites. Exp Parasitol
2001, 98(3):152–161.
22. Gonzalez-Ceron L, Rodriguez MH, Chavez-Munguia B, Santillan F, Nettel JA,
Hernandez-Avila JE: Plasmodium vivax: impaired escape of Vk210
phenotype ookinetes from the midgut blood bolus of Anopheles
pseudopunctipennis. Exp Parasitol 2007, 115(1):59–67.
23. Zakeri S, Barjesteh H, Djadid ND: Merozoite surface protein-3alpha is a
reliable marker for population genetic analysis of Plasmodium vivax.
Malar J 2006, 5:53.24. Galinski MR, Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, Barnwell
JW: Plasmodium vivax merozoite surface protein-3 contains coiled-coil
motifs in an alanine-rich central domain. Mol Biochem Parasitol 1999,
101(1–2):131–147.
25. Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, Galinski MR,
Barnwell JW: Extensive polymorphism in the Plasmodium vivax merozoite
surface coat protein MSP-3alpha is limited to specific domains.
Parasitology 2002, 125(Pt 5):393–405.
26. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, Zhou G, Chen H, Yan G,
Sattabongkot J: Genetic diversity and multiple infections of Plasmodium
vivax malaria in Western Thailand. Am J Trop Med Hyg 2003, 68(5):613–619.
27. Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, Su
XZ: Local adaptation and vector-mediated population structure in
Plasmodium vivax malaria. Mol Biol Evol 2008, 25(6):1245–1252.
28. Kain KC, Brown AE, Webster HK, Wirtz RA, Keystone JS, Rodriguez MH,
Kinahan J, Rowland M, Lanar DE: Circumsporozoite genotyping of global
isolates of Plasmodium vivax from dried blood specimens. J Clin Microbiol
1992, 30(7):1863–1866.
29. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F,
Looareesuwan S, White NJ, Snounou G: Practical PCR genotyping
protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 2005,
4(1):20.
30. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP: Polymorphism at
the merozoite surface protein-3alpha locus of Plasmodium vivax: global
and local diversity. Am J Trop Med Hyg 1999, 61(4):518–525.
31. Kim JR, Imwong M, Nandy A, Chotivanich K, Nontprasert A, Tonomsing N,
Maji A, Addy M, Day NP, White NJ, et al: Genetic diversity of Plasmodium
vivax in Kolkata. India. Malar J 2006, 5:71.
32. Adak T, Valecha N, Sharma VP: Plasmodium vivax polymorphism in a
clinical drug trial. Clin Diagn Lab Immunol 2001, 8(5):891–894.
33. Peakall R, Smouse PE: GenAlEx 6.5: genetic analysis in Excel. Population
genetic software for teaching and research--an update. Bioinformatics
2012, 28(19):2537–2539.
34. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP,
Felger I: Evaluation of Plasmodium vivax genotyping markers for
molecular monitoring in clinical trials. J Infect Dis 2009, 199(7):1074–1080.
35. Mason J: Patterns of Plasmodium vivax recurrence in a high-incidence
coastal area of El Salvador, C. A. Am J Trop Med Hyg 1975, 24(4):581–585.
36. Hulden L, Heliovaara K: Natural relapses in vivax malaria induced by
Anopheles mosquitoes. Malar J 2008, 7:64.
37. Rodriguez MH, Betanzos-Reyes AF, Hernandez-Avila JE, Mendez-Galvan JF,
Danis-Lozano R, Altamirano-Jimenez A: The participation of secondary
clinical episodes in the epidemiology of vivax malaria during pre- and
post-implementation of focal control in the state of Oaxaca. Mexico. Am J
Trop Med Hyg 2009, 80(6):889–895.
38. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schopflin S,
Stanisic D, Betuela I, Blood-Zikursh M, et al: Differential patterns of
infection and disease with P. falciparum and P. vivax in young Papua
New Guinean children. PLoS One 2010, 5(2):e9047.
39. Hanna JN, Ritchie SA, Eisen DP, Cooper RD, Brookes DL, Montgomery BL: An
outbreak of Plasmodium vivax malaria in Far North Queensland, 2002.
Med J Aust 2004, 180(1):24–28.
40. Havryliuk T, Ferreira MU: A closer look at multiple-clone Plasmodium vivax
infections: detection methods, prevalence and consequences. Mem Inst
Oswaldo Cruz 2009, 104(1):67–73.
41. Rodriguez MH, Betanzos-Reyes AF: Plan to improve malaria control towards
its elimination in Mesoamerica. Salud Publica Mex 2011, 53(3):S333–348.
42. WHO: Malaria elimination. A field manual for low and moderate endemic
countries. Geneva; 2007. http://whqlibdoc.who.int/publications/2007/
9789241596084_eng.pdf.
43. Kim JR, Nandy A, Maji AK, Addy M, Dondorp AM, Day NP, Pukrittayakamee
S, White NJ, Imwong M: Genotyping of Plasmodium vivax reveals both
short and long latency relapse patterns in Kolkata. PLoS One 2012,
7(7):e39645.
44. Cogswell FB: The hypnozoite and relapse in primate malaria.
Clin Microbiol Rev 1992, 5(1):26–35.
45. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y,
Chalermrut K, Bangchang KN, Harinasuta T: High dose of primaquine in
primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994,
88(2):218–219.
Gonzalez-Ceron et al. Parasites & Vectors 2013, 6:109 Page 12 of 12
http://www.parasitesandvectors.com/content/6/1/10946. Carmona-Fonseca J, Maestre A: Prevention of Plasmodium vivax malaria
recurrence: efficacy of the standard total dose of primaquine
administered over 3 days. Acta Trop 2009, 112(2):188–192.
47. Hanf M, Stephani A, Basurko C, Nacher M, Carme B: Determination of the
Plasmodium vivax relapse pattern in Camopi. French Guiana Malar J 2009,
8:278.
48. Boulos M, Amato Neto V, Dutra AP, Di Santi SM, Shiroma M: Frequency of
malaria relapse due to Plasmodium vivax in a non-endemic region
(Sao Paulo, Brazil). Rev Inst Med Trop Sao Paulo 1991, 33(2):143–146.
49. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU: Recurrent
parasitemias and population dynamics of Plasmodium vivax
polymorphisms in rural Amazonia. Am J Trop Med Hyg 2009, 81(6):961–968.
50. Coatney GR, Cooper WC, Young MD: Studies in human malaria. XXX. A
summary of 204 sporozoite-induced infections with the Chesson strain
of Plasmodium vivax. J Natl Malar Soc 1950, 9(4):381–396.
51. White NJ: Malaria. In Manson's Tropical Diseases. 21st edition. Edited by
Cook GC, Zumla AI. London: WB Sounders; 2003:1205–1295.
52. Moon SU, Lee HW, Kim JY, Na BK, Cho SH, Lin K, Sohn WM, Kim TS: High
frequency of genetic diversity of Plasmodium vivax field isolates in
Myanmar. Acta Trop 2009, 109(1):30–36.
53. Haghdoost AA, Mazhari S, Bahaadini K: Estimating the relapse risk of
Plasmodium vivax in Iran under national chemotherapy scheme using a
novel method. J Vector Borne Dis 2006, 43(4):168–172.
54. Mangoni AA, Jackson SH: Age-related changes in pharmacokinetics and
pharmacodynamics: basic principles and practical applications. Br J Clin
Pharmacol 2004, 57(1):6–14.
55. Maslin J, Cuguillere A, Bonnet D, Martet G: Malaria attack: a very late
relapse due to Plasmodium vivax. Bull Soc Pathol Exot 1997, 90(1):25–26.
doi:10.1186/1756-3305-6-109
Cite this article as: Gonzalez-Ceron et al.: Molecular and epidemiological
characterization of Plasmodium vivax recurrent infections in southern
Mexico. Parasites & Vectors 2013 6:109.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
